Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 177

Results For "Pan"

9194 News Found

BioNTech co-founders launch new mRNA venture, aiming to revolutionize next-gen therapies
News | March 14, 2026

BioNTech co-founders launch new mRNA venture, aiming to revolutionize next-gen therapies

The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission


Lilly issues urgent warning over potentially dangerous Tirzepatide-B12 compounds
News | March 14, 2026

Lilly issues urgent warning over potentially dangerous Tirzepatide-B12 compounds

Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound


Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug
Clinical Trials | March 14, 2026

Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug

The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days


Biogen unveils promising new data for Salanersen in kids with SMA
News | March 14, 2026

Biogen unveils promising new data for Salanersen in kids with SMA

Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains


Single-use gloves misused across India, raising health risks
Healthcare | March 14, 2026

Single-use gloves misused across India, raising health risks

One task, one interaction, one pair, experts advocate


Aster DM bags overwhelming shareholder backing for merger with Quality Care
Healthcare | March 14, 2026

Aster DM bags overwhelming shareholder backing for merger with Quality Care

The endorsement follows overwhelming support for the share swap preceding the merger,


Natural Biogenex joins forces with Fermbox Bio to boost fermentation-based biomanufacturing
Biotech | March 14, 2026

Natural Biogenex joins forces with Fermbox Bio to boost fermentation-based biomanufacturing

The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand


MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel
Biotech | March 14, 2026

MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel

The protections extend through at least 2035, with the potential for further extensions